PHI News Room
All News and Press Releases
Enter any phrase or word you would like to search for and click .
PostNews: Press Release
The last day of trading in warrants of series TO 4 is on 1 October 2024
The 1st of October 2024 is the last day of trading in warrants of series TO 4, which were issued in connection with Phase Holographic Imaging PHI AB’s preferential rights issue of units that was carried out in 2022. The exercise period runs until 3 October 2024.
PostNews: Press Release
PHI announces significant order agreement from Altium for 20 HoloMonitor systems
PHI is excited to announce a significant order agreement from Altium for 20 HoloMonitor systems, which will be shipped in the second half of 2024.
PostNews: Interim Report
Interim Report 1 2024/25
The first quarter of 2024 has so far been a period of steady course and strategic positioning for Phase Holographic Imaging. Most notably, PHI has been very active around the globe in forming important academic and sales partnerships during this summer and preparing for future growth.
PostNews: Press Release
The exercise period for warrants of series TO 4 commences today
Today is the first day for the exercise of Phase Holographic Imaging PHI AB’s warrants of series TO 4 which were issued in connection with the preferential issue of units that the Company carried out during 2022. The period lasts until October 3, 2024.
PostNews: Press Release
The exercise price for warrants of series TO 4 has been set to SEK 4.63 per new share
PHI announces that the exercise price for warrants of series TO 4 has been set at SEK 4.63 per new share.
PostNews: Press Release
Bulletin from extraordinary general meeting in Phase Holographic Imaging PHI AB (publ) 2 September 2024
Phase Holographic Imaging PHI AB (publ) (“PHI” or the “Company”) held an extraordinary general meeting on 2 September 2024. The following resolutions were passed at the meeting.
Company News
Here, you see PHI featured in recent news and find previous CEO commentaries.
BioStock: PHI’s CEO reflects on global roadshow success
BioStock contacted CEO Patrik Eschricht to learn about the team’s achievements on their global roadshow this early summer.
BioStock: PHI on how TO 3 proceeds will be used
BioStock talked to CEO Patrik Eschricht to learn how the TO 3 proceeds would be used.
BioStock: PHI´s CEO comments on latest advancements
BioStock reached out to PHI´s CEO, Patrik Eschricht, to learn more about the visions moving forward.
CERN seminar: The Promise of Regenerative Medicine and AI
During this seminar, Peter Egelberg, Founder of PHI, will present the work carried out by PHI in the development of time-lapse cytometry instrumentation and software.
